1379079-58-9

Upstream product

• 1379079-51-2 (R)-benzyl 3-((tert-butoxycarbonylamino)(phenyl)methyl)-3-nitroazetidine-1-carboxylate 
• 1379079-52-3 (S)-benzyl 3-(((tert-butoxycarbonyl)amino)(phenyl)methyl)azetidine-1-carboxylate 
• 1379079-54-5 (S)-tert-butyl (azetidin-3-yl(phenyl)methyl)carbamate 
• 137049-00-4 1-methyl-1H-imidazole-4-sulfonyl chloride 

Downstream Products

• 1246495-15-7 2,4-dichloro-N-((1-((1-methyl-1H-imidazol-4-yl) sulfonyl)azetidin-3-yl)(phenyl) methyl) benzamide 
• 1246495-14-6 2,4-dichloro-N-((1-((1-methyl-1H-imidazol-4-yl) sulfonyl)azetidin-3-yl)(phenyl) methyl) benzamide 
• 1379079-60-3 (S)-(1-((1-methyl-1H-imidazol-4-yl)sulfonyl)azetidin-3-yl)(phenyl)methanamine 

Relevant academic research and scientific papers

Chiral proton catalysis of secondary nitroalkane additions to azomethine: Synthesis of a potent GlyT1 inhibitor

The first enantioselective synthesis of a potent GlyT1 inhibitor is described. A 3-nitroazetidine donor is used in an enantioselective aza-Henry reaction catalyzed by a bis(amidine)-triflic acid salt organocatalyst, delivering the key intermediate with 92% ee. This adduct is reductively denitrated and converted to the target through a short sequence, thereby allowing assignment of the absolute configuration of the more potent enantiomer.